Generics Maker Says Drug-Safety Program Gets Abused

By Leigh Kamping-Carder

Law360, New York (November 13, 2009, 4:06 PM ET) -- Teva Pharmaceuticals Ltd. has reportedly complained to the Federal Trade Commission that it has been unable to purchase bulk quantities of certain pharmaceuticals because brand-name drug companies are using a federal drug-safety program to unfairly limit competition.

The program, enacted in 2007, limits the sale of certain riskier drugs in an effort to guard against abuse. But Teva said in a letter to the FTC that GlaxoSmithKline PLC, Novartis AG and Bayer AG had all refused to sell the Israel-based generics maker supplies of certain drugs,...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles